ReveraGen BioPharma, Inc.   Report issue

For profit Phase 2
Founded: Rockville MD United States (2008)

Organization Overview

First Clinical Trial
2015
NCT02415439
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

ReveraGen BioPharma | ReveraGen BioPharma, Inc.

Active Ingredients

Drugs in Phase 2 Trials (2)

prednisone (meticorten) (1 trial)

vamorolone (Agamree) (9 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Colitis (Phase 2)

Colitis, Ulcerative (Phase 2)

Muscular Dystrophies (Phase 2)

Muscular Dystrophy, Duchenne (Phase 2)

Ulcer (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 9
  • # of Trial APIs: 2